Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis

Lorgelly P. K., Atkinson M., Lakhanpaul M., Smyth A. R., Vyas H., Weston V., Stephenson T.

Source: Eur Respir J 2010; 35: 858-864
Journal Issue: April
Disease area: Paediatric lung diseases, Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Lorgelly P. K., Atkinson M., Lakhanpaul M., Smyth A. R., Vyas H., Weston V., Stephenson T.. Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis. Eur Respir J 2010; 35: 858-864

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Source: Eur Respir J 2004; 24 : 644-648
Year: 2004



Intravenous steroids in the treatment of community-acquired pneumonia (CAP)
Source: Eur Respir J 2004; 24: Suppl. 48, 50s
Year: 2004

Efficacy of sequential intravenous (i.v.) to oral (p.o.) moxifloxacin in hospitalized patients with community-acquired pneumonia (CAP) due to m. pneumoniae or chlamydia spp.
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007


Oral antibiotics prior to hospitalisation for community-acquired pneumonia
Source: Eur Respir J 2008; 31: 478-479
Year: 2008


Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006

LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma
Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues
Year: 2015


Efficacy of corticosteroids in hospital treated community-acquired pneumonia
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012

Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015

Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013



Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment
Source: Annual Congress 2009 - Pulmonary infections
Year: 2009


Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP)
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007


Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005

Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France
Source: Eur Respir J 2003; 22: Suppl. 45, 151s
Year: 2003

Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010



Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP)
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008

Meta analysis of hospitalized patients with community-acquired pneumonia (CAP) treated with levofloxacin
Source: Eur Respir J 2004; 24: Suppl. 48, 188s
Year: 2004

Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006

Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006


Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients
Source: Annual Congress 2011 - COPD management
Year: 2011


The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 2s
Year: 2006